NASHVILLE, Tenn., Feb. 18, 2025 — Quokka Care, a healthcare technology solutions provider advancing the Remote Patient Monitoring (RPM) space, announced today the successful completion of a strategic growth investment led by prominent health tech entrepreneur Ray Guzman, Montecito Medical Real Estate, and other notable healthcare investors. This funding marks a significant milestone in Quokka Care’s journey to redefine how chronic conditions are managed remotely through its innovative, patient-centered approach.

The investment validates Quokka Care’s unique strategy of enhancing patient outcomes while reducing the operational burden on healthcare providers. With this backing, Quokka Care will accelerate its expansion, enhance its technology platform, and broaden its reach to healthcare provider organizations nationwide.

Closing Gaps in Care

Unlike traditional RPM, Quokka Care’s solution goes beyond data collection to support holistic, patient-centered care. Combining personalized health coaching with seamless integration into existing Electronic Health Record (EHR) workflows, Quokka Care ensures meaningful engagement between patients and their care teams.

“This investment validates our innovative approach to RPM,” said Guy Crossley, CEO of Quokka Care. “We’re partnering with respected healthcare and technology leaders to establish a new standard in patient-centered remote care that prioritizes outcomes and engagement.”

“Quokka Care ensures that care teams can proactively close care gaps, increase compliance, and anticipate potential health events—all while reducing the administrative burden on physicians,” said Chip Conk, CEO of Montecito Medical Real Estate. “We’re excited to invest in and partner with Quokka Care to bring this comprehensive solution to our providers and the communities they serve.”

Building on Proven Success

Quokka Care leverages the ArrowHealth Bridge platform, which integrates RPM data, patient messaging, and telehealth directly into clinicians’ workflows. This approach eliminates the need for additional tools or processes, streamlining the experience for care teams and enabling them to focus on patient outcomes.

“Quokka Care’s forward-thinking model addresses critical gaps in traditional RPM by focusing on outcomes over data,” said Ray Guzman, CEO of SwitchPoint Ventures. “This investment reflects our shared belief in a future where technology and human touch come together seamlessly.”

Patient and Provider-Centric

Quokka Care addresses longstanding challenges in RPM, including EHR integrations, workflow disruptions, administrative burdens, and patient engagement challenges. The company’s dedicated health coaches and program managers support practices in achieving measurable results, setting a new standard for remote care.

“Quokka Care’s vision aligns perfectly with the future of healthcare,” said Crossley. “We’re shaping a world where technology and personal care work in harmony to benefit every patient and provider.”

About Quokka Care

Quokka Care is a healthcare technology company that offers a turnkey remote patient monitoring (RPM) solution focused on improving patient outcomes and practice revenue. Led by an experienced executive team, including Guy Crossley (CEO), Mark Dose (COO), and Mike Jobe (CCO), the company combines innovative technology with personalized care. At the heart of the program are dedicated health coaches who regularly engage with patients, track their progress, and provide personalized support. Quokka Care also offers operational support, client success advisors to help clinics achieve their RPM goals, and a proprietary web-based bridge technology that seamlessly integrates RPM data with existing electronic health record (EHR) systems.

Media Contact:
Shanna Belott
3107707857
[email protected] 

SOURCE Quokka Care

NEW YORK, Feb. 18, 2025 — As traditional finance continues its migration on-chain, SkyBridge Capital Founder and Managing Partner, Anthony Scaramucci, is excited about Kinto’s upcoming token launch, scheduled for February 18, 2025. SkyBridge invested $150,000 in Kinto.

“I’m an early investor and supporter of Kinto through SkyBridge,” said Scaramucci. “Kinto’s modular exchange opens up tremendous possibilities for institutional investors to deploy capital on-chain and tokenize products without counterparty risk.”

Kinto brings the feature set of centralized exchanges to decentralized finance. The platform currently serves approximately 75,000 verified users and manages approximately $62 million in total value locked (TVL).

“Kinto has built a functioning product, established a verified user base, and created steady revenue streams. Tokenized finance represents a significant and exciting opportunity,” noted Scaramucci.

Recently, large institutional investors such as Brevan Howard Digital’s Abu Dhabi branch deployed $20 million in assets on Kinto, enabling participation in the on-chain financial ecosystem.

Previous investors include AJ Scaramucci, Founder & Managing Partner, Solari Capital who incubated the company, with participation from Spartan Group, Parafi, Kraynos, Soft Holdings, Deep Ventures, Modular, Tane and Robot Ventures.

The token launch is an important milestone in Kinto’s product rollout.

About SkyBridge Capital
SkyBridge Capital is a global alternative investment firm specializing in financial technology, digital assets, venture capital, and multi-manager solutions. The firm, founded by Anthony Scaramucci in 2005, has allocated over half of SkyBridge’s assets under management to digital assets, an emerging asset class that is reshaping the future of finance.

About Kinto
Kinto is a modular exchange that provides access to opportunities in DeFi through its tailored blockchain and non-custodial smart wallet. The platform combines institutional-grade security with retail accessibility, built on a custom Layer 2 stack with Chain Abstraction technology. Core features include User-Owned KYC, insured wallets, chain abstracted swaps and lending markets, and a native Hyperliquid integration for advanced trading. Kinto is working to offer users an easy and simple way to move on and off-chain without using CEXs. Founded to bridge traditional and decentralized finance, Kinto has raised $7M from SkyBridge Capital, Parafi, Robot Ventures, and strategic angels.

Media Contact
Prosek Partners, on behalf of SkyBridge Capital
[email protected]

SOURCE SkyBridge Capital

PALM BEACH GARDENS, Fla., Feb. 18, 2025 — Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions, today announced that its venture group, Carrier Ventures, is leading an investment and technology partnership with ZutaCore®, a disruptive innovator of two-phase direct-to-chip liquid cooling technology for data centers. This investment aligns with Carrier’s strategy of providing high-tech, integrated cooling solutions to meet the critical cooling needs of data center customers. The global data center cooling market is projected to reach $20 billion by 2029, and liquid cooling is projected to grow at a 39% CAGR over the same period.

“Direct-to-chip liquid cooling is essential for next-generation data centers as AI drives an increase in global demand for high-density computing,” said Ajay Agrawal, Senior Vice President, Global Services, Business Development & Chief Strategy Officer, Carrier. “We continue to invest in cutting-edge technologies to ensure Carrier is fully prepared for the data center needs for advanced cooling systems. Our partnership with ZutaCore will help tackle the cooling challenges of tomorrow’s data centers and will ensure optimal performance and energy-efficient solutions for our customers.”

“Our partnership with Carrier marks a major milestone for ZutaCore as we continue to redefine the cooling industry at scale,” said Erez Freibach, Co-Founder and CEO, ZutaCore. “By integrating our waterless liquid cooling technology with Carrier’s expertise in intelligent climate and energy solutions, we are delivering a comprehensive and sustainable solution tailored specifically to the AI market. This collaboration enables us to meet the growing demands of next-generation AI and data processing workloads with energy-efficient solutions, revolutionizing data center cooling for AI factories worldwide.”

ZutaCore is a San Jose, CA-based provider of direct-to-chip, waterless liquid cooling solutions. ZutaCore’s next-generation liquid cooling technology is designed to cool the hottest processors with 100% heat reuse, paving the way toward a lower-emission data center industry. Its HyperCool® technology – a direct-to-chip, waterless, direct liquid cooling solution – enables high sustained performance, server densification and reduced power usage, critical for meeting the power demands of today’s high performance, artificial intelligence and machine learning data center workloads.

Carrier’s investment in ZutaCore is part of its broader ambition to redefine data center thermal management. With the recent announcement of Carrier QuantumLeap™, the company introduced a fully integrated suite of innovative, energy-efficient solutions for data center thermal management, designed to optimize the entire thermal lifecycle.

Through Carrier Ventures, Carrier invests in innovations and disruptive technologies enabling the future of building and cold chain management.

For more information about Carrier Ventures’ portfolio companies, visit Corporate.Carrier.com/carrier-ventures.

About Carrier 
Carrier Global Corporation, global leader in intelligent climate and energy solutions, is committed to creating solutions that matter for people and our planet for generations to come. From the beginning, we’ve led in inventing new technologies and entirely new industries. Today, we continue to lead because we have a world-class, diverse workforce that puts the customer at the center of everything we do. For more information, visit corporate.carrier.com or follow Carrier on social media at @Carrier.

Contact:
Jason Shockley
561-542-0207
[email protected]

CARR-IR

SOURCE Carrier Global Corporation

• Dr Mozayeni brings deep experience in biotech corporate strategy and business development
• Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington’s disease into the clinic

CAMBRIDGE, England, Feb. 18, 2025 — LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease, myotonic dystrophy type 1, and other triplet repeat expansion diseases, today announces the appointment of Dr Cyrus Mozayeni as its Chair of the Board of Directors.

Dr Mozayeni is a highly experienced biotech entrepreneur with a track record of more than 20-years spearheading growth and strategic business development for life sciences companies. Dr Mozayeni is currently CEO of Pheon Therapeutics (Pheon), a leading antibody-drug conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers. He recently led Pheon through a successful $120 million Series B financing round in May 2024.

Dr David Reynolds, Chief Executive Officer of LoQus23 Therapeutics, commented: “Following our successful fundraise late last year, the Company is at a pivotal moment as we progress towards IND-enabling studies of our potent allosteric small molecule MSH3 inhibitor, part of the MutSβ complex. Cyrus brings a wealth of world class biotech expertise to guide us at this critical time and will help us to deliver treatments for patients with Huntington’s and similar triplet repeat expansion diseases.” 

Dr Cyrus Mozayeni, newly appointed Chair of the Board of Directors of LoQus23, added: “The science behind LoQus23’s unique approach is hugely promising. Several recent high-profile papers provide unequivocal support for the development of treatments targeting somatic CAG repeat expansion – the foundation of our approach. I look forward to working with the Board and the Leadership Team to help deliver the lead asset into the clinic and beyond.”

As an Entrepreneur-in-Residence at Atlas Venture, Dr Mozayeni launched Vedere Bio and served as President & CEO from inception through to its sale to Novartis. Before joining Atlas Venture, Dr Mozayeni was co-founder of CODA Biotherapeutics, and Oncorus, where he served as President and CBO. He also served as VP and Global Head of Business Development and Alliance Management at Nasdaq listed Bluebird Bio, where his efforts led to a clinical-stage CAR T-cell program (ABECMA®, idecabtagene vicleucel) in collaboration with Celgene, and a successful IPO. A qualified Doctor of Medicine, Dr Mozayeni is a graduate of the University of Virginia School of Medicine and holds both an MBA from the Kellogg School of Management of Northwestern University and an Sc.B. in Neuroscience from Brown University.

In October 2024, LoQus23 announced the successful close of its £35 million Series A financing round led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund and Novartis Venture Fund. The Company has since established a platform of assays and small molecule series of MutSα and MutSβ inhibitors which are therapeutically relevant in numerous triplet repeat diseases, including Huntington’s Disease.

Notes to Editors

About LoQus23 Therapeutics Ltd
LoQus23 is a biotech company based in Cambridge, UK, developing small molecule somatic expansion inhibitors for the treatment of Huntington’s Disease and other triplet repeat expansion diseases. Huntington’s disease is an autosomal dominant neurodegenerative disorder for which there is currently no disease modifying treatment available and which currently has 30,000 patients in the US alone.

LoQus23’s approach has the potential to stop DNA instability and therefore slow neurodegeneration in these diseases. LoQus23 is focused on using a structure-based approach to design small molecule drugs, which can offer more convenient administration than other approaches. Oral small molecule drugs have a strong track record in treating complex brain diseases and provide greater convenience for patients compared with other advanced treatment modalities. LoQus23’s lead programme, a potent allosteric small molecule MSH3 inhibitor, part of the MutSβ  complex, will enter the clinic in 2026.

LoQus23 has a highly experienced leadership team, built on world-class science. It was originally established in 2019 by Dr David Reynolds, Dr Caroline Benn, and Dr Ruth McKernan CBE, FMedSci, Entrepreneurs in Residence at SV Health Investors’ Dementia Discovery Fund, which also acted as the initial seed investor. In October 2024, the Company closed a successful £35 million Series A financing round led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund and Novartis Venture Fund.

For more information, please visit: www.loqus23.com

SOURCE LoQus23 Therapeutics

Company Raises $3.85M in Seed Funding led by Caduceus Capital Partners, with Participation
from Bread and Butter Ventures; Announces Collaboration with Mayo Clinic

SAN FRANCISCO, Feb. 14, 2025 — VoiceCare AI, a healthcare administration general intelligence (HAGI) company, announced plans to automate back-office conversations and super-staff the workforce through the application of generative AI. The company’s agentic architecture platform is built to optimize and ease administrative burden and radically improve operational efficiency. With $3.85 million in funding led by Caduceus Capital Partners, and participation from Bread and Butter Ventures, VoiceCare AI seeks to improve access, adherence, and outcomes for patients and the healthcare workforce, putting the focus back on patient engagement.

Every year, countless calls with long hold times occur in the healthcare system, transferring and copying data, verifying statuses and follow-ups, or starting a process. According to McKinsey & Company, healthcare administration in the United States currently accounts for $1 trillion of the $4.5 trillion total healthcare spend, and more than 90% of healthcare-related calls are still being handled manually between humans. VoiceCare AI is looking to tackle this challenge head-on with “Joy,” its human-like voice AI agent built to support long, complex, and highly nuanced conversations and extended hold times.

“Imagine a world where the time spent on manual phone calls and faxes is replaced by meaningful patient interactions. With generative AI, we want to make this a reality,” said Parag Jhavari, founder and CEO of VoiceCare AI. “By automating conversations in a way that feels genuinely human, we seek to give back time to healthcare professionals so they can focus on high-order patient care, driving radical efficiencies with every conversation. That’s why we created “Joy,” our voice AI agent. We want to give healthcare professionals more time to focus on what truly matters—caring for patients.”

VoiceCare AI also announced a pilot with Mayo Clinic to employ its intelligent voice automation for use cases including patient pre-authorization and benefit confirmations within three separate areas – the Department of Neurology, Department of Pediatrics, and Medical and Administrative Support Operations.

The funding will support team expansion, enhanced sales and marketing efforts, and continued investment in enhancing platform accuracy, security and compliance.

“At Caduceus Capital Partners, we’re passionate about funding technologies that improve efficiency and reduce administrative costs. VoiceCare AI has the potential to provide a much-needed solution to providers, and we’re proud to support this team as they grow the business,” said Dave Vreeland, senior managing partner at Caduceus Capital Partners.

“VoiceCare’s technology has potential to empower clinical and healthcare staffing teams to focus on patient care and alleviate administrative burdens,” said Mary Grove, Managing Partner at Bread and Butter Ventures. “They are attempting to solve pain points we’ve all experienced as patients and driving value for patients, providers, and payers. We’re thrilled to back Parag’s big vision to tech-enable the administrative layer of healthcare.”

How it Works

Every year healthcare administrators and providers spend 60-80% of their time on insurance- and billing-related tasks instead of patient care. VoiceCare AI transforms B2B voice conversations through intelligent automation. Its AI platform handles payer communication, from benefits verification to prior authorizations and claims follow-ups. By automating time-consuming calls, the company seeks to free staff from hours of hold times while maintaining detailed documentation and a call summary of every interaction. The system is designed to integrate seamlessly with existing workflows and provides near real-time status updates.

The company’s technology leverages advanced multi-modal, multimodal agentic architecture with reinforcement learning from human feedback (RLHF) and proprietary healthcare conversational data to achieve a near-perfect call completion accuracy rate, with a majority of calls completed autonomously using AI. VoiceCare’s development team takes a safety-focused approach as the platform is HIPAA compliant and SOC 2 Type II attested.

The VoiceCare advisory board has deep healthcare, technical and AI experience. They include: Andrew Vaz, Mary Grove, Paul Conley, Mark Nathan, James Fan, and Dr. Sheena Menezes.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About VoiceCare AI

VoiceCare AI is a healthcare administration general intelligence (HAGI) company built to automate back-office conversations and super-staff the workforce through the application of generative AI. The company’s AI voice-based automation and agentic AI architecture massively eliminates administrative burden and improves operational efficiency. “Joy,” its human-like voice AI agent, is capable of supporting long, complex, and highly nuanced conversations and extended hold times. VoiceCare AI has raised $3.85 million in seed funding led by Caduceus Capital Partners, and participation from Bread and Butter Ventures. For more information, visit us at Voicecare AI and follow us on LinkedIn and YouTube.

Media Contact
Audrey Mann Cronin
[email protected] 

SOURCE VoiceCare AI

Company Opens Fundraising Round to Scale AI-Driven Diagnostics & Treatment Simulations

DENVER, Feb. 14, 2025 — NeuralCure AI, an emerging leader in AI-powered healthcare technology, today unveiled its groundbreaking platform capable of compressing a century of medical research into a single day. By leveraging AI-driven diagnostics and rapid treatment protocol simulations, NeuralCure AI is pioneering perfect-match treatment solutions that seamlessly integrate into research and patient care, accelerating breakthroughs at an unprecedented pace.

To scale its technology and expand its global healthcare impact, the company has officially opened its fundraising round, inviting investors to participate in shaping the future of precision healthcare.

Revolutionizing Healthcare with AI-Powered Simulations

NeuralCure AI’s proprietary technology runs over 10,000 treatment simulations daily on digital twins, rapidly identifying and refining the most effective patient-specific treatment strategies for conditions such as cancer, neurodegenerative diseases, and metabolic disorders.

“For decades, medical research has been trapped in slow, incremental cycles,” said Orin Wilson, spokesperson for NeuralCure AI. “We’ve shattered that bottleneck. Our AI-driven simulations can process the equivalent of 100 years of medical discoveries in a single day, unlocking perfect-match treatment protocols that seamlessly integrate into research studies and patient care.”

How NeuralCure AI is Transforming Healthcare

NeuralCure AI’s platform delivers AI-driven solutions for both diagnostics and treatment planning by:

• Aggregating and integrating diverse data sources, including imaging scans, genomic profiles, real-world environmental data, and neurological patterns, providing insights that other AI models overlook.
• Instantly analyzing medical images and videos to detect diseases and abnormalities with unmatched precision.
• Running thousands of rapid treatment protocol simulations per day to refine patient-specific interventions.
• Developing AI-powered “perfect match” treatment protocols that integrate with research studies or real-world treatment plans.
• Using neuro-programming interfaces to activate the body’s natural healing processes.

“We’re not just predicting disease, we’re engineering the fastest, most effective way to treat it,” Wilson added. “By unlocking AI-driven precision medicine, we’re making healthcare faster, smarter, and more accessible than ever before.”

Fundraising Round Now Open to Accelerate Growth

To further develop and deploy its AI-powered medical solutions, NeuralCure AI has launched a new fundraising round. This investment will enable the company to:

• Expand AI-driven research partnerships with leading hospitals, universities, and medical institutions
• Scale digital twin treatment simulations to refine life-saving therapies
• Deploy AI diagnostics and treatment protocols into real-world applications with current customers

“This is the future of healthcare,” said Ryan Doelling, early investor from thebad.company . “NeuralCure AI isn’t just improving medical diagnostics, it’s transforming how we approach disease prevention, treatment, and recovery. Their ability to simulate thousands of treatments per day and develop precision-tailored protocols is a game-changer for the industry.”

Partner with NeuralCure AI

NeuralCure AI is actively seeking partnerships with research organizations, healthcare providers, medical imaging companies, and treatment facilities to integrate its AI-powered solutions.

To explore investment or partnership opportunities contact [email protected].

About NeuralCure AI

NeuralCure AI is a cutting-edge AI healthcare technology company redefining medical research and patient care through AI-driven diagnostics, medical imaging analysis, and neuro-programming solutions. By accelerating discovery cycles and perfecting treatment protocols, NeuralCure AI is making the impossible possible, compressing decades of medical advancement into days.

Media Contact:
[email protected] 
NeuralCure AI

NeuralCure AI: Advancing Healthcare at the Speed of AI.

SOURCE NeuralCure AI, Inc.

ASHEVILLE, N.C., Feb. 13, 2025 — Surus, an institutional-grade asset management and custody platform for onchain finance, announced today that it received regulatory approval from the North Carolina Commissioner of Banks to open Surus Trust Company, a wholly owned subsidiary.

Surus’s mission is to accelerate and improve the onchain financial ecosystem. Powered by Surus Trust Company, the Surus platform equips builders with the tools to create, sell, and manage tokenized assets within a time-tested and regulated legal structure. The platform’s offerings include fiduciary asset management services, custody for traditional and crypto native assets, brokerage and payment system connectivity, compliance tools, and multichain tokenization capabilities.

“As finance moves onchain, the market needs digitally native infrastructure that is flexible enough to support tokenized assets of all kinds within compliant, bankruptcy-remote legal structures,” said Patrick Murck, founder and CEO of Surus, “We’re eager to partner with the builders making the onchain future of finance a reality.”

“North Carolina has been a terrific partner in creating this de novo digitally-native financial institution and we look forward to continuing our work with the North Carolina Commissioner of Banks and staff.”

In Q1 2025, Surus is partnering with companies to service three lines of business:

• Reserve Management for Tokenized Assets and Stablecoins: Supporting creators of tokenized financial products and stablecoins with customizable asset reserve management and settlement services.
• Digital Asset Trusts: Enabling offchain investors to securely and transparently access onchain investment opportunities, such as owning curated digital asset portfolios or participating in DeFi ecosystems.
• End-to-End Tokenization and Custom Fiduciary Services: Working with startups and traditional firms alike to go from 0 to 1 with tokenized financial products powered by Surus’s platform.

Surus completed an $8 million series seed bringing their total amount of funding raised to over $10 million. The latest financing was led by Castle Island Ventures with participation from Propel Ventures, Restive Ventures, Protagonist, Protocol VC, and Plural VC.

“The tokenization of dollars and other assets is the unambiguous killer app of blockchains so far,” said Nic Carter, GP of Castle Island Ventures. “There is a distinct lack of credible regulated intermediaries in the sector, and Surus is poised to change that. I am thrilled to be backing Surus and joining the board.”

For more information about Surus and its services, visit surus.io

Contact:

[email protected] 

SOURCE Surus

Brevan Howard Digital, Karatage, Token Bay, Pharsalus and others join in supporting Soter’s mission to provide specialized insurance products for the digital asset sector

ABU DHABI, UAE, Feb. 13, 2025 — Soter Insure, a provider of specialized insurance products tailored to the digital asset economy, has successfully closed its Series A funding round, led by Galaxy, with participation from Brevan Howard Digital, Karatage, Token Bay, Pharsalus and others.

Headquartered in Abu Dhabi and operating out of Bermuda, with offices in London, New York and Dubai, Soter Insure was incubated by Further Ventures and WebN Group. The company offers specialized digital asset insurance products for financial institutions, including Asset Loss, Directors & Officers (D&O), and Smart Contract Failure coverage, uniquely denominated in both fiat and native digital assets.

As the Web3 space continues to evolve, the lack of adequate insurance products and scarce capacity has been a significant barrier to broader adoption. Soter Insure addresses this gap by offering comprehensive insurance solutions tailored to the unique risks of decentralized technologies, thereby instilling confidence in institutional and retail participants.

The investment will support Soter Insure’s expansion, bolstering its underwriting and technology teams to scale operations across key markets.

“Our mission at Soter is to set a new standard for risk management in the digital assets space. We are proud to have the support of Galaxy and our other Series A investors as we work to build innovative insurance products that meet the unique needs of the market. With this funding, we’ll continue to expand our offerings and grow our footprint globally, providing clients with trusted and transparent risk management solutions,” said Henson Orser, Founder and CEO of Soter Insure.

Mike Novogratz, Founder and CEO of Galaxy, added, “Galaxy is excited to support Soter Insure in their mission to bring innovative insurance solutions to the digital asset ecosystem. Their tailored approach to risk management meets a crucial industry need, empowering digital asset holders and operators with confidence. We are excited to contribute to their growth and global expansion.”

For more information about Soter Insure, visit soter.insure.

About Soter Insure
Soter Insure is a leading provider of specialized insurance solutions for the digital asset economy. With a focus on institutional investors, Soter offers a range of innovative insurance products that address the unique risks of the blockchain ecosystem. Soter Insure is committed to providing robust, transparent, and secure risk management solutions. For more information, visit www.soter.insure

SOURCE Soter Services North America LLC

SAN FRANCISCO, Feb. 13, 2025 — Tofu, the unified AI platform for B2B marketing teams, today announced it has raised $12 million in Series A funding. The investment was led by SignalFire, with participation from HubSpot Ventures, Tau Ventures, Correlation Ventures, Alumni Ventures, SH Fund, Riverside Ventures, Eudemian Ventures, and Han Bridge Capital, alongside a notable group of angel investors. Existing investors Index Ventures, Stage 2 Capital, and Liquid 2 Ventures also participated in the round.

Tofu’s unified platform addresses a critical pain point for marketing teams: the overwhelming proliferation of martech tools. By consolidating campaign execution under one roof, Tofu enables GTM teams to create personalized, omni-channel campaigns at scale without the burden of managing multiple point solutions.

Over the past year, Tofu has experienced tremendous growth, with a 12x increase in revenue and a 36x surge in content generated on the platform. Tofu has gained traction with marketing teams of various sizes, from fast-growing startups to enterprise organizations like RingCentral, Check Point and Bluecore.

“This capital accelerates our mission to build a unified AI platform for GTM teams. We’re grateful for our investors’ support and customer feedback, which drive us to create a comprehensive, one-stop solution that helps marketing teams scale campaigns across a wide range of use cases,” said EJ Cho, Ço-founder and CEO of Tofu.

Companies leveraging Tofu have experienced significant improvements in their marketing performance and revenue growth. The approach to consolidate omni-channel campaigns under one umbrella has enabled teams to execute campaigns more efficiently, resulting in a tremendous increase in engagement and conversion across multiple channels. Teams using the platform have seen up to 75% reduction in campaign creation time, and a 230% increase in engagement rates across their marketing channels. Tofu’s platform caters to diverse GTM teams and their specific needs whether it’s demand generation, content marketing, lifecycle marketing, event marketing, digital marketing, or outbound SDR campaigns.

“Tofu is the end of one-size-fits-none marketing, and the true beginning of generative marketing, through omni-channel hyper-personalized campaigns that scale. Customers have raved about the 10x+ lift in content output for time strapped marketing teams and 20 percent downstream conversion lift. There’s no better team to capitalize on the opportunity, as EJ, Elaine and Honglei represent the perfect combination of AI/ML expertise and customer empathy as GTM practitioners” – Wayne Hu, Partner @ Signal.

For more information about Tofu and its unified AI platform for GTM teams, visit tofuhq.com.

About Tofu:

Tofu is an omnichannel marketing platform that helps B2B marketing teams scale their campaigns by personalizing content for different customer segments and repurposing content across channels. With its flexible workflows, marketing teams can efficiently create and execute campaigns for demand generation, content marketing, lifecycle marketing, event marketing and more. Tofu enables marketing teams to build cohesive, on-brand campaigns at scale while reducing martech bloat and improving efficiency.

SOURCE Tofu